刚刚！以岭药业过敏性鼻炎一类新药芪防鼻通片进入国家医保

Core Viewpoint - The National Medical Insurance Drug List for 2025 has been officially published, with Yiling Pharmaceutical's innovative drug Qifang Nizhong Pian being included for the first time [1] Group 1: Drug Approval and Market Entry - Qifang Nizhong Pian is an innovative traditional Chinese medicine specifically indicated for the treatment of persistent allergic rhinitis, addressing a clinical gap in medication [1] - The drug received approval from the National Medical Products Administration in January 2025 and was registered by the Macao Special Administrative Region's government on July 12, 2025, marking it as the first innovative traditional Chinese medicine approved in Macao [1]